Veru (VERU)
(Delayed Data from NSDQ)
$1.33 USD
-0.04 (-2.92%)
Updated May 10, 2024 04:00 PM ET
After-Market: $1.33 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
VERU 1.33 -0.04(-2.92%)
Will VERU be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for VERU based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VERU
Veru Inc. (VERU) Just Flashed Golden Cross Signal: Do You Buy?
Baxter (BAX) to Report Q1 Earnings: What's in the Cards?
VERU: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes Veru (VERU) a New Buy Stock
After Plunging -15.61% in 4 Weeks, Here's Why the Trend Might Reverse for Veru Inc. (VERU)
Bio-Rad Laboratories (BIO) to Post Q4 Earnings: What Awaits?
Other News for VERU
Buy Rating Affirmed on Veru Amid Strong Clinical Prospects and Solid Financial Position
Veru Inc (VERU) Q2 2024 Earnings Call Transcript Highlights: Strategic Focus and Financial Recovery
VERU Stock Earnings: Veru Misses EPS, Beats Revenue for Q2 2024
Veru Inc. (VERU) Fiscal 2024 Q2 Earnings: Clinical Advances Amid Financial Strains
Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program